Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Michael D. Prados(University of California, San Francisco), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), Mitchel S. Berger(University of California, San Francisco), Jane Rabbitt(UCSF Helen Diller Family Comprehensive Cancer Center), Anne Fedoroff(UCSF Helen Diller Family Comprehensive Cancer Center), Jennifer Ayers-Ringler(Mayo Clinic), Hannah Carliner(UCSF Helen Diller Family Comprehensive Cancer Center), Rupa Parvataneni(UCSF Helen Diller Family Comprehensive Cancer Center), Penny K. Sneed(University of California, San Francisco), Rebecca DeBoer(UCSF Helen Diller Family Comprehensive Cancer Center), Kathleen R. Lamborn(University of California, San Francisco), David Stokoe(Enzo Life Sciences (United States)), Nicholas Butowski(University of California, San Francisco), Susan M. Chang(University of California, San Francisco), Michael W. McDermott(UCSF Helen Diller Family Comprehensive Cancer Center), Andrew T. Parsa(University of California, San Francisco), Scott R. VandenBerg(University of California San Diego), Paul Kabuubi(UCSF Helen Diller Family Comprehensive Cancer Center), Margaretta Page(UCSF Helen Diller Family Comprehensive Cancer Center), C. David James(Mayo Clinic in Arizona)
Cited by 377
Related Papers
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
|Nature|2008|7.8k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k